Alzamend Neuro, Inc. (ALZN)
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
ALZN Insider Trading Activity
ALZN Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $1,361 | 5 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| AULT MILTON C III | 5 | $1,361 | 0 | $0 | $1,361 |
About Alzamend Neuro, Inc.
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Insider Activity of Alzamend Neuro, Inc.
Over the last 12 months, insiders at Alzamend Neuro, Inc. have bought $1,361 and sold $0 worth of Alzamend Neuro, Inc. stock.
On average, over the past 5 years, insiders at Alzamend Neuro, Inc. have bought $4.74M and sold $63,434 worth of stock each year.
Highest buying activity among insiders over the last 12 months: AULT MILTON C III () — $1,361.
The last purchase of 100 shares for transaction amount of $68 was made by AULT MILTON C III () on 2025‑03‑12.
List of Insider Buy and Sell Transactions, Alzamend Neuro, Inc.
| 2025-03-12 | AULT MILTON C III | 100 0.0019% | $0.68 | $68 | +2.01% | |||
| 2024-08-06 | AULT MILTON C III | 75 0.0107% | $2.75 | $206 | -42.79% | |||
| 2024-07-31 | AULT MILTON C III | 25 0.0034% | $3.74 | $93 | -62.18% | |||
| 2024-04-19 | AULT MILTON C III | 1,000 0.0148% | $0.69 | $688 | -75.15% | |||
| 2024-04-01 | AULT MILTON C III | 334 0.005% | $0.91 | $304 | -80.34% | |||
| 2024-01-05 | AULT MILTON C III | 2,000 0.0308% | $1.06 | $2,127 | -58.00% | |||
| 2024-01-05 | AULT MILTON C III | 5,000 0.0737% | $1.02 | $5,093 | -58.00% | |||
| 2023-12-26 | AULT MILTON C III | 10 percent owner | 500 0.007% | $0.90 | $450 | -53.77% | ||
| 2023-12-22 | AULT MILTON C III | 10 percent owner | 200 0.0029% | $0.92 | $185 | -52.22% | ||
| 2023-09-26 | Katzoff David J | Chief Financial Officer | 53,000 0.0564% | $0.19 | $10,234 | -69.37% | ||
| 2023-05-24 | AULT MILTON C III | 10 percent owner | 18,000 0.0185% | $0.59 | $10,705 | -86.53% | ||
| 2023-04-28 | Jackman Stephan | Chief Executive Officer | 37,000 0.0372% | $0.54 | $19,999 | -67.51% | ||
| 2023-03-22 | McGrath Lynne Fahey | director | 10,000 0.0101% | $0.43 | $4,350 | -47.91% | ||
| 2023-03-17 | AULT MILTON C III | 10 percent owner | 5,000 0.0055% | $0.43 | $2,149 | -42.00% | ||
| 2023-03-16 | AULT MILTON C III | 10 percent owner | 4,000 0.0045% | $0.50 | $2,006 | -48.95% | ||
| 2023-02-15 | AULT MILTON C III | 10 percent owner | 1,000 0.001% | $0.60 | $597 | -50.44% | ||
| 2022-12-28 | AULT MILTON C III | director | 3,100 0.0033% | $0.56 | $1,745 | -8.49% | ||
| 2022-12-27 | AULT MILTON C III | director | 900 0.0009% | $0.59 | $532 | -18.01% | ||
| 2022-12-21 | AULT MILTON C III | director | 5,000 0.0054% | $0.81 | $4,050 | -35.56% | ||
| 2022-12-19 | AULT MILTON C III | director | 23,000 0.023% | $0.82 | $18,813 | -40.35% |
Insider Historical Profitability
| AULT MILTON C III | 77368 1.1727% | $52,393.61 | 106 | 4 | <0.0001% | |
| Katzoff David J | Chief Financial Officer | 81000 1.2277% | $54,853.20 | 1 | 0 | <0.0001% |
| GUSTAFSON MARK | 60000 0.9094% | $40,632.00 | 0 | 2 | ||
| Jackman Stephan | Chief Executive Officer | 45500 0.6897% | $30,812.60 | 1 | 0 | |
| McGrath Lynne Fahey | director | 10000 0.1516% | $6,772.00 | 1 | 1 |
Historical Insider Profitability vs. Competitors
Alzamend Neuro, Inc. (ALZN) | $18,881,323 | 88 | -48.96% | $4.47M |
$296,936 | 37 | -18.12% | $4M | |
$31,129 | 22 | -11.96% | $6.19M | |
$960,082 | 17 | -6.29% | $3.52M | |
$51,865 | 17 | -38.70% | $6.16M | |
$1,558,469 | 16 | -26.98% | $4.56M | |
$139,855 | 11 | -32.84% | $5.33M | |
$309,830 | 10 | -55.78% | $4.18M | |
$111,748 | 9 | -47.72% | $3.4M | |
$100,375 | 8 | -51.85% | $3.4M | |
$253,451 | 7 | -35.51% | $4.42M | |
$726,438 | 4 | -72.85% | $5.47M | |
$76,299 | 4 | 11.60% | $6.49M | |
$14,530 | 3 | 62.23% | $5.77M | |
$1,057,000 | 3 | 5.27% | $3.89M | |
$608,453 | 3 | -53.52% | $3.34M | |
$105,480 | 3 | -97.42% | $5.35M | |
$165,600 | 2 | -3.58% | $3.69M | |
$1,049,630 | 1 | -74.91% | $6.38M |
ALZN Institutional Investors: Active Positions
| Increased Positions | 9 | +60% | 93,316 | +221.64% |
| Decreased Positions | 4 | -26.67% | 22,088 | -52.46% |
| New Positions | 8 | New | 93,285 | New |
| Sold Out Positions | 3 | Sold Out | 18,309 | Sold Out |
| Total Postitions | 20 | +33.33% | 113,330 | +169.18% |
ALZN Ownership Change vs Market
Institutional Investor Ownership
| Geode Capital Management, Llc | $28.00 | 0.67% | 33,540 | +33,540 | New | 2024-12-31 |
| Citadel Advisors Llc | $25.00 | 0.61% | 30,638 | +30,638 | New | 2024-12-31 |
| Truist Financial Corp | $13.00 | 0.31% | 15,498 | 0 | 0% | 2024-12-31 |
| Renaissance Technologies Llc | $12.00 | 0.3% | 15,000 | +15,000 | New | 2024-12-31 |
| Virtu Financial Llc | $10.00 | 0.25% | 12,719 | +12,719 | New | 2024-12-31 |
| Blackrock, Inc. | $3.00 | 0.08% | 3,973 | 0 | 0% | 2024-12-31 |
| Ubs Group Ag | $1.00 | 0.02% | 820 | +820 | New | 2024-12-31 |
| Citigroup Inc | $0 | 0.01% | 544 | +544 | New | 2024-12-31 |
| Tower Research Capital Llc (Trc) | $0 | 0.01% | 388 | -3,779 | -90.69% | 2024-12-31 |
| Bank Of America Corp /De/ | $0 | <0.01% | 136 | +31 | +29.52% | 2024-12-31 |